Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.45 |
| ▸ | NOS3 | P29474 | 8/20 | 0.43 |
| ▸ | NOS1 | P29475 | 8/20 | 0.43 |
| ▸ | NOS2 | P35228 | 8/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30607548 | 0.83 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL6048518 | 0.80 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3HTR2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL6048587 | 0.79 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3HTR2ACYP1A2 | |
| SCHEMBL27663986 | 0.76 | SLC6A4 (0.43) | SLC6A4NOS3NOS1NOS2CYP1A2 | |
| SCHEMBL11078831 | 0.75 | TSHR (0.47) | CYP1A2 | |
| SCHEMBL29668668 | 0.72 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL151809 | 0.72 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL4193657 | 0.72 | ALDH1A1 (0.45) | SLC6A4SLC6A2NOS2CYP1A2CYP2D6 | |
| SCHEMBL6048563 | 0.72 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR2ACYP1A2 | |
| SCHEMBL6048536 | 0.71 | TAAR1 (0.57) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202953-B1 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2006-08-30 | — | — | EP | claimed |
| US-6710080-B2 | ANALGESICS | GRUENENTHAL GMBH (DE) | 2004-03-23 | — | — | US | claimed |
| JP-2003506426-A | — | — | 2003-02-18 | — | — | JP | claimed |
| US-20020198251-A1 | Substituted 2-dialkylaminoalkylbiphenyl derivatives | GRUENENTHAL GMBH (DE) | 2002-12-26 | — | — | US | claimed |
| EP-1202953-A2 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | Grünenthal GmbH (DE) | 2002-05-08 | — | — | EP | claimed |
| WO-2001010816-A2 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | Grünenthal GmbH (DE) | 2001-02-15 | — | — | WO | claimed |
| EP-1202953-B1 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2006-08-30 | — | — | EP | disclosed |
| US-6710080-B2 | ANALGESICS | GRUENENTHAL GMBH (DE) | 2004-03-23 | — | — | US | disclosed |
| US-20020198251-A1 | Substituted 2-dialkylaminoalkylbiphenyl derivatives | GRUENENTHAL GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| EP-1202953-A2 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | Grünenthal GmbH (DE) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010816-A2 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | Grünenthal GmbH (DE) | 2001-02-15 | — | — | WO | disclosed |
| US-4434100-A | TRANQUILIZING, ANTICONVULSANTS, ANXIOLYTIC | CIBA-GEIGY CORPORATION (US) | 1984-02-28 | — | — | US | disclosed |
| US-4356176-A | TRANQUILIZERS, ANTICONVULSANT | CIBA-GEIGY CORPORATION (US) | 1982-10-26 | — | — | US | disclosed |
| US-4315926-A | ANXIOLYTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1982-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198251-A1 | Substituted 2-dialkylaminoalkylbiphenyl derivatives | LIPA, PKD1, PKD2 | SLC6A4 1586/4885SLC6A2 1499/4885SLC6A3 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.